NASDAQ:ARDX Ardelyx Q3 2026 Earnings Report $3.42 +0.03 (+0.88%) Closing price 09/30/2026 04:00 PM EasternExtended Trading$3.40 -0.02 (-0.44%) As of 09/30/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Ardelyx EPS ResultsActual EPSN/AConsensus EPS -$0.01Beat/MissN/AOne Year Ago EPSN/AArdelyx Revenue ResultsActual RevenueN/AExpected Revenue$129.22 millionBeat/MissN/AYoY Revenue GrowthN/AArdelyx Announcement DetailsQuarterQ3 2026Date10/29/2026TimeAfter Market ClosesConference Call DateThursday, October 29, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Ardelyx Earnings HeadlinesRobbins LLP is Investigating Allegations that Ardelyx, Inc. Misled Investors Regarding the True State of the Company's Commercial Performance and Growth Prospects for its Two ...September 30 at 6:20 PM | theglobeandmail.comARDX UPCOMING DEADLINE: Levi & Korsinsky Alerts Ardelyx, Inc. Stockholders of Securities Class Action - Contact the FirmSeptember 30 at 12:51 PM | prnewswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. | InvestorPlace (Ad)Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer AwardsSeptember 30 at 8:01 AM | globenewswire.comAnalyzing Ardelyx (NASDAQ:ARDX) & Phibro Animal Health (NASDAQ:PAHC)September 30 at 5:44 AM | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines – ARDXSeptember 29 at 5:01 PM | globenewswire.comSee More Ardelyx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ardelyx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ardelyx and other key companies, straight to your email. Email Address About ArdelyxArdelyx (NASDAQ:ARDX) is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal conditions. The company’s lead product candidates and marketed medicines are designed to address disorders involving the regulation of phosphate and other substances in the digestive system. Ardelyx markets XPHOZAH (tenapanor) in the United States for reducing serum phosphorus in adults with chronic kidney disease on dialysis. Tenapanor works locally in the gastrointestinal tract by inhibiting the sodium/hydrogen exchanger 3, thereby reducing intestinal phosphate absorption. The company also markets IBSRELA (tenapanor) for the treatment of irritable bowel syndrome with constipation in adults. Founded in 2007 and headquartered in Waltham, Massachusetts, Ardelyx serves the U.S. market through its commercial operations and continues to develop therapies for gastrointestinal and cardiorenal diseases. The company is led by Michael Raab, who serves as president and chief executive officer.View Ardelyx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundArhaus Has New Momentum—Could Other Furniture Stocks Be Next?Bernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks Upcoming Earnings NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
